Improve cognition through brain stimulation
- Trial ID
- NCT06399731
- Official Title
- NEuroStimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease: an Acceptability Cross-over Study
- Goal
- Improve cognition through brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Amsterdam UMC
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson Disease, Mild Cognitive Impairment
- Interventions
- High-frequency (10Hz) rTMS, Anodal tDCS
Summary For Families
The goal is to see whether noninvasive brain stimulation is acceptable to people with Parkinson's and can help mild cognitive problems by improving the brain circuits that support thinking. The trial uses a cross-over design so participants try both high-frequency 10 Hz rTMS, which delivers magnetic pulses to boost activity in targeted brain areas, and anodal tDCS, which applies a gentle direct electrical current to increase neuronal excitability; both are meant to support cognition while participants remain on their usual Parkinson medications. They are looking for people with neurologist-diagnosed Parkinson's and mild cognitive impairment (for example MoCA 21,25 or mild deficits on neuropsychological tests), Hoehn and Yahr stage under 4, and stable dopaminergic meds; people with dementia, seizure history, implanted devices, certain skin or medical conditions, pregnancy, or MRI contraindications are excluded.
Locations
- Amsterdam UMC, Amsterdam, North Holland, Netherlands
Frequently Asked Questions
- What is this trial testing?
- This trial is studying High-frequency (10Hz) rTMS. The goal is to see whether noninvasive brain stimulation is acceptable to people with Parkinson's and can help mild cognitive problems by improving the brain circuits that support thinking. The trial uses a cross-over design so participants try both high-frequency 10 Hz rTMS, which delivers magnetic pulses to boost activity in targeted brain areas, and anodal tDCS, which applies a gentle direct electrical current to increase neuronal excitability; both are meant to support cognition while participants remain on their usual Parkinson medications. They are looking for people with neurologist-diagnosed Parkinson's and mild cognitive impairment (for example MoCA 21,25 or mild deficits on neuropsychological tests), Hoehn and Yahr stage under 4, and stable dopaminergic meds; people with dementia, seizure history, implanted devices, certain skin or medical conditions, pregnancy, or MRI contraindications are excluded.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 6 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.